Khalifa M A, Lacher D A, Lage J M, Mannel R S, Walker J L, Angros L H, Min K W
Department of Pathology, Memorial University of Newfoundland, Saint John's, Canada.
Cancer Detect Prev. 1997;21(6):532-9.
Recently reported morphologic and molecular genetic evidence suggests that some ovarian carcinomas arise from their benign and low malignant potential (LMP) counterparts. In order to help reach a better understanding of ovarian tumorigenesis, we studied a wide range of gene products involved in cellular growth regulation in archival material obtained from three groups of tumors with graduated malignant potential. Immunohistochemical staining was performed for Ki-67, proliferating cell nuclear antigen (PCNA), epidermal growth factor receptor (EGFR), HER-2/neu-encoded receptor protein, p53 gene product, and multidrug resistance gene product (P-glycoprotein). The expression of EGFR, HER-2/neu-encoded receptor protein, and mutant p53 product was significantly lower in LMP tumors than in carcinomas (p < 0.05). HER-2/neu immunopositivity was more prevalent in adenocarcinomas than in LMP tumors, and the proportion of HER-2/neu-positive adenocarcinomas increased with the progression of the disease. The staining differences between LMP tumors and adenocarcinomas with antibodies against Ki-67, PCNA, and P-glycoprotein were not statistically significant. Immunohistochemical detection of EGFR, HER-2/neu, and p53 in ovarian epithelial tumor is relevant to ovarian tumorigenesis. It could serve as a powerful tool for the pursuit of retrospective studies focused on these important biologic markers.
最近报道的形态学和分子遗传学证据表明,一些卵巢癌起源于其良性和低恶性潜能(LMP)的对应物。为了有助于更好地理解卵巢肿瘤发生,我们研究了从三组具有不同恶性潜能的肿瘤获得的存档材料中涉及细胞生长调节的多种基因产物。对Ki-67、增殖细胞核抗原(PCNA)、表皮生长因子受体(EGFR)、HER-2/neu编码的受体蛋白、p53基因产物和多药耐药基因产物(P-糖蛋白)进行免疫组织化学染色。LMP肿瘤中EGFR、HER-2/neu编码的受体蛋白和突变型p53产物的表达明显低于癌(p<0.05)。HER-2/neu免疫阳性在腺癌中比在LMP肿瘤中更常见,并且HER-2/neu阳性腺癌的比例随着疾病进展而增加。LMP肿瘤与腺癌之间用抗Ki-67、PCNA和P-糖蛋白抗体染色的差异无统计学意义。卵巢上皮肿瘤中EGFR、HER-2/neu和p53的免疫组织化学检测与卵巢肿瘤发生有关。它可以作为一个强大的工具用于开展针对这些重要生物学标志物的回顾性研究。